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Abstract
Background: HIV prevalence is high in Liangshan, China (1.1 %). In 2012, people who inject drugs (PWID) in
Xichang, the capital city, contributed to 60.0 % of the HIV infections. The goal of the current study was to examine
the feasibility of implementing pharmacy-delivered harm reduction services (PDHRS) for PWID.
Methods: Face-to-face structured interviews with 403 PWID included questions on PWID’s experiences of syringe
services and their specific experiences, acceptance, and potential usage of PDHRS.
Results: There were some reports of harassment/bad treatment from pharmacists (12.2 %) and police (17.6 %).
Non-prescription syringe sales (NPSS) from pharmacies in single piece were the main source (82.1 %) of syringes.
72.5 % of PWID reported visiting 31.5 % of the identified pharmacies. Most (74.7 %) PWID disposed of their used
syringes by throwing them away. Only one PWID brought used syringes back to a pharmacy in the past 30 days.
Half of the PDHRS, such as printed materials about HIV, Hepatitis C and STIs; risk reduction services; (16.9 %) and
sharps container to dispose of syringes (0.2 %) were offered by a few pharmacies (<20 % for each service). The
acceptance rates among PWID toward currently offered services were high (≥91.1 %). All potential PDHRS were
acceptable by most (68–95.3 %) PWID, and correspondingly 67–94.5 % of PWID reported they would use each
service if offered.
Conclusions: NPSS from pharmacies provided many PWID in Liangshan with new syringes. However, disposal of
used syringes was problematic. At the time of investigation, half of 16 assessed PDHRS were already available in
pharmacies in Xichang. PWID were ready to use all the potential PDHRS and14 of 16 PDHRS were feasible to
provide. HIV testing kits may be available in pharmacies in the future. Many pharmacy-delivered harm reduction
services are feasible and acceptable among PWID in Xichang, China.
Background
The first indigenous human immunodeficiency virus
(HIV) cases in China were reported among heroin users
in the Yunnan province in 1989 [1]. The overall HIV
prevalence (0.058 %) in China remains low, but HIV
prevalence among people who inject drugs (PWID) re-
mains high [2]. Due to country-wide responses [3–6], by
the end of 2011, Methadone Maintenance Treatment
(MMT) (738 clinics covering 13.3 % of the total PWID)
and Needle Exchange Program (NEP) (over 900 sites de-
livering more than 12 million clean syringes annually)
have been scaled up in China [4, 7, 8]. Syringe distribu-
tion rates (per PWID per year) in China are greater than
the global average, including levels in the United States
and Russia [8]. HIV prevalence among PWID has been
decreasing from 12.0 % in 2005 [3], 9.3 % in 2009 to
6.4 % in 2011 [4]. In certain areas, such as Liangshan Yi
Autonomous Prefecture (Liangshan), Sichuan province,
sharing syringes and other injection equipment are still
common among PWID [5, 6, 9]. Between March 2004
and December 2012, HIV prevalence among PWID from
11 methadone clinics in Liangshan was found to be
25.4 % [7].
In 2012, China accounted for approximately 20 % of
the global numbers of PWID [10, 11]. Sichuan province
ranked 5th in the number of PWID in China [2]; most
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are from Liangshan [12, 13]. Liangshan has been part of
the major drug trafficking routes in China for more than
100 years, and heroin use is common in Liangshan [14].
HIV incidence in Liangshan increased dramatically,
accounting for 81.5 % of the total HIV/AIDS cases in
the past 5 years [15]. According to the Asian Epidemic
Model, PWID accounted for 52.3 % of the HIV infections
in Liangshan in 2013, and are anticipated to be respon-
sible for 39.1 % by 2020 [16].
Providing sterile syringes to PWID is a cost effective
method of HIV prevention [17]. NEP and pharmacies
are the major sources of sterile syringes [18]. Yet perceived
discrimination [19], internalized stigma [20], and lack of
stigma management strategies [21] impede PWID from
using formal health services such as NEP [20, 22, 23].
Internationally, community pharmacies have been
providing services such as non-prescription syringe
sales (NPSS), HIV-testing, vaccinations, educational
materials, and coupon syringe programs. Other services
are potentially available in pharmacies, such as providing
methadone, naloxone for overdose treatment, safer injec-
tion training programs, containers to dispose of used sy-
ringes, on-site disposal, testing for hepatitis, and directly
observed therapy for PWID [18, 21, 24–38]. However,
PWID have reported problems accessing available harm
reduction services. Refusals to sell syringes and demands
for picture identification or prescriptions have been docu-
mented even when purchasing syringes is legal and there
is no official requirements for providing identification or a
prescription [18, 29, 30, 35–37].
In China, syringes are considered medical devices.
Pharmacies that sell syringes are required to obtain a
“Medical Devices Operation Enterprises permit”, which
is issued by the provincial bureau of the Food and Drug
Administration (FDA) and supervised by the Prefecture
FDA [39]. In Guangxi Province, distribution of phar-
macy vouchers for syringes, ampoules of sterile water for
injection, and condoms has been previously tested [40].
A survey among 324 PWID from detoxification centers
in Yunnan Province documented that their major
sources of syringes were pharmacies and health clinics
[41]. Between 2008 and 2011, NEP among 19 counties
in Yunnan had been implemented at pharmacies, clinics,
and through peer educators [42].
NPSS to PWID in Liangshan have not been reported
in previous literature, and it was unclear whether PWID
would utilize potential PDHRS. Xichang, the capital of
Liangshan, has a population is more than 600,000 [6]. In
2012, the official estimated number of PWID was 2250,
and drug use contributed to 60 % of HIV infections [23].
The HIV prevalence among PWID in Xichang was
found to be 11.3 % [43] in 2002, 17.8 % in 2004 [44],
and 18.0 % in 2012 [23]. There is one MMT clinic, three
MMT outpatient service sites, and three NEP sites. In
2012, there were more than 400 pharmacies. The goal of
the present study was to examine the feasibility of a
range of PDHRS for PWID in Xichang.
Methods
This study was a cross-sectional study design, and the
protocols were approved by both institutional review
boards (IRBs) from Johns Hopkins Bloomberg School of
Public Health (JHSPH) and the West China School of
Public Health (WCSPH). The survey was developed as
part of a multisite study on the feasibility of using phar-
macies for PWID’s health services [23]. The protocol
and questionnaire were initially written in English. The
questionnaire was translated into Chinese, reviewed both
by the US and China study team, and piloted. The sur-
vey took approximately 30 min to administer. The local
collaborator, Xichang Skin Disease and Prevention
Center (XSDPC), is a government agency responsible
for HIV/AIDS prevention and control. The research
team selected Xichang methadone clinic and detoxifica-
tion center to recruit eligible PWID. The study inclu-
sion criteria for PWID were: 1) 18 years of age or over
and 2) had injected drugs within the past 30 days. From
April to May, 2012, investigators from WCSPH and
staff from XSDPC were trained as interviewers and
conducted face-to-face structured interviews. Snowball
sampling methods were used. After completing their in-
terviews, PWID were encouraged to inform other
PWID about the study. A total of 403 PWID were re-
cruited from Xichang detoxification center (66.7 %),
MMT clinic (15.6 %), communities (7.4 %), MMT out-
patient service sites (6.7 %), and rehabilitation center
(3.5 %). As participants volunteered for the study and
came to the clinics for the interviews, response rates
could not be calculated.
Before completing an interview, eligible participants
provided informed consent, and 50 yuan (~USD 8) com-
pensation was provided after completing the surveys.
Condoms and safe injection supplies were provided as
well as appropriate referrals. The survey questions in-
cluded demographic characteristics, self-reported HIV sta-
tus, methods of obtaining and disposal of syringes,
experiences of syringe services in pharmacies, and the per-
ceptions and potential utilizations of 16 potential PDHRS.
The 16 PDHRS included: printed materials about HIV,
Hepatitis C, and sexually transmitted infection(STI) risk
reduction; blood pressure check; vaccinations for Hepatitis
A and B; information about how to prevent abscesses;
overdose medication (naloxone); sharps container to dis-
pose of syringes; a written medical, drug treatment, and
social service referrals; free condoms; HIV testing; training
or information about how to inject safely; training or in-
formation about preventing overdoses; syringe exchange;
disposal of used syringes; directly dispensing methadone;
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and free syringes. The response options toward potential
PDHRS were binary (yes or no).
SPSS 22.0 (IBM, USA) was used for analyses. For uni-
variate analysis, range and median for interval variables
and frequencies for nominal variables were conducted.
Fisher’s exact test was used for comparing the frequen-
cies of receiving and giving used syringes among PWID
and P < 0.05 as a level of statistical significance.
Results
The characteristics of 403 participants are presented in
Table 1. Almost all (95.8 %) PWID had been in prison/jail
or forced drug treatment; 71.0 % reported that they had
been tested for HIV, and among them 70.6 % said they were
HIV negative, 14.7 % HIV positive, and 14.7 % did not
know their status. The earliest test among the participants
was reported in 1994. Overall, 41.7 % were HIV negative,
8.7 % HIV positive, 8.7 % had been tested but did not know
their status, and 29.0 % had not been tested.
In the past 30 days, 2.7, 19.4, and 77.9 % of PWID, re-
spectively reported “always”, “at least once”, and “never”
using a used syringe; 3.5 % “always”, 25.3 % “at least
once”, and 71.2 % “never” passed their syringe to some-
one else to use after they had used it. It is interesting to
note that PWID reported receiving fewer used syringes
than they distributed (Fisher’s exact test, p < 0.01).
Receiving and disposing used syringes
Most (72.0 %) PWID agreed with the statement that
“it was easy to get new sterile syringes”, and a large
percentage (81.1 %) reported having purchased a syringe
in a pharmacy in the last 30 days, with a median of six sy-
ringes for regular purchase. The most frequent (74.7 %)
method for syringe disposal was throwing syringes
away, and 24.3 % reported that they left syringes
where they injected. Only 1 PWID brought used syringes
to a pharmacy (Table 2).
Experiences of buying syringes from pharmacies
Most (82.1 %) PWID reported having purchased a syr-
inge in a pharmacy in the last 12 months, over half
(63.5 %) reported that the minimum number of syringes
that they could buy in a pharmacy in Xichang was one,
and 59.3 % of participants reported the price for one syr-
inge was one Chinese Yuan (~$0.16). Almost two-thirds
(64.5 %) of PWID agreed with the statement “it’s gener-
ally hard for me to go to the pharmacy during the hours
they are open.” A similar proportion (65.2 %) preferred
to buy syringes at a pharmacy where they buy over-the-
counter (OTC) or prescription drugs; 43.8 % reported
that they used pharmacies in the same neighborhood/re-
gion where they live. There were 309 (76.7 %) PWID
who named the pharmacies where they bought syringes
most of time, and 124 unique pharmacies were identi-
fied. One pharmacy was frequently visited by 23(5.7 %)
PWID and 31.5 % of the 124 identified pharmacies were
visited by more than one PWID (Table 3).
When buying syringes in pharmacies in the last
12 months, 18.6 % of PWID reported that their requests
were declined, and 12.2 % were harassed or treated
poorly at the pharmacy (Table 4). Some (17.6 %) PWID
reported that they had been stopped or poorly treated by
the police near a pharmacy.
Pharmacy-delivered services
Among the 16 listed potential services in the pharma-
cies, eight were currently offered by ≤16.9 % of pharma-
cies. The most commonly offered service was printed
materials about HIV, Hepatitis C, and STI risk reduction
services (16.9 %), and the least common were sharps
containers (0.2 %) and written medical or social service
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referrals (0.2 %). The acceptance rates were high among
services currently offered (≥91.1 %). The eight services
that were associated with harm reduction, such as HIV
testing and free syringes, were not currently offered in
pharmacies. The 16 potential harm reduction services
were acceptable to most PWID (68–95.3 %), and most
(67–94.5 %) PWID reported that they would use the
service if offered (Table 5).
Discussion
At the time of this study, government funded detoxifica-
tion center, MMT, and NEP services were available, but
no government funded HIV prevention funds provided
to pharmacies for harm reduction services in Xichang.
The first available harm reduction service reported in
this sample of PWID was HIV testing, which occurred
in 1994, 5 years after the first large national HIV out-
break among PWID in Yunnan [1]. As almost all
(95.8 %) PWID had been in prison or jail or forced drug
treatment where HIV testing is mandatory, it was ex-
pected that over 95 % should have been tested. However
the self-report HIV testing rate was only 71.0 %. There-
fore, it is probable that HIV positive status was under-
reported [23]. In this study, syringe sharing was lower
than previously reported [9], which may be due in part
to country-wide responses to HIV by increasing the
levels of syringe distribution [3–6, 9].
Table 2 Obtaining and disposing of syringes in the Last 30 days among PWID from Xichang, China 2012 (n = 403)
Sources of syringes Syringes disposal
Source No. (%) Syringes usually
obtained median(range)*
Source No. (%)
Pharmacy 327(81.1) 6(1–180) Throwing syringes away 302(74.7)
Medical facility 93(23.1) 6(1–500) Left syringes where they injected 98(24.3)
Someone else obtain syringes from pharmacy 48(11.9) 3(1–100) Buried or burned syringes 72(17.9)
NEP 36(8.9) 10(2–100) Brought syringes to a NEP 20(5.0)
Syringe seller/drug dealer 25(6.2) 4.5(1–50) Put syringes in a sharps container, or
soda or laundry bottle, then threw it away
20(5.0)
Bought from a friend, relative, or acquaintance
(PWID or non-PWID)
10(2.5) 5(2–20) Gave syringes to someone else to take to
a NEP for them
18(4.5)
Received free from a friend, relative or acquaintance
(PWID or non-PWID)
10(2.5) 5(1–25) Gave syringes to an outreach worker or
peer educator
10(2.5)
From someone who said they got them at a NEP 6(1.5) 10(1–50) Brought syringes to a pharmacy 1(0.2)
From an outreach worker 2(0.5) 21.5(8–35) -
Used prescription for syringes because of diabetic or
other medical condition
1(0.2) 20(20–20) -
Abbreviations: People who inject drugs (PWID) needle exchange program (NEP)
*: median and range were calculated only among PWID who obtained syringes from the source
Table 3 Frequently visited pharmacies for syringes purchase














1 85 68.5 85 21.1
2 15 12.1 30 7.4
3 4 3.2 12 3.0
4 2 1.6 8 2.0
5 2 1.6 10 2.5
6 4 3.2 24 6.0
7 2 1.6 14 3.5
8 3 2.4 24 6.0
10+ 7 5.6 102 25.3
total 124 100.0 309 76.7
Abbreviations: People who inject drugs (PWID) €: n = 403
Table 4 Syringes purchase experiences in pharmacies among





the past 30 days
(median(range))£
Declined to sell syringes 75(18.6) 3(0–100)
Harassed or treated badly at the
pharmacy
49(12.2) 3(0–30)
Asked what the syringes will be
used for
30(7.4) 3(1–30)
Refused to sell ‘single’ syringes 12(3.0) 2(0–10)
Asked to sign a log-book or re-
quired written personal information
3(0.7) 2(1–3)
Asked to show a photo
identification card
3(0.7) 1.5(1–2)
PWID refers to people who inject drugs
£: median and range were calculated only among PWID who experienced in
the last 12 months
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Though most PWID (>90 %) were recruited from
harm reduction sites, pharmacies, rather than these sites,
were the main source of obtaining syringes. Pharmacies
appear to be a critical and highly accessible source of sy-
ringes, although 18.6 % of participants reported that they
had experienced a refusal to their request to purchase
syringes. Almost all PWID did not dispose of their used
syringes safely [45]. Though eight of 16 PDHRS were
available for PWID, but only at low level (<20 %), the ac-
ceptance rates were high, and PWID were highly sup-
portive of additional PDHRS.
Not surprising, free syringes from pharmacies are not
currently offered. The success of NPSS is as part of the
pharmacy business. Although NPSS from pharmacies
were common, operation hours created a significant bar-
rier against purchasing syringes. Perceived discrimination
may also prevent PWID from purchasing syringes from
pharmacies [30]. In other studies in Yunnan, PWID
reported pretending to buy OTC drugs when purchasing
syringes to avoid discrimination [41, 42]. In this study,
most PWID wanted to buy syringes from pharmacies
where they buy OTC or prescription drugs, but less than
half chose pharmacies at the same neighborhood/region
where they live. These findings suggest that fears of dis-
crimination and stigma either from pharmacists/pharmacy
staff or from others in their neighborhood are potential
barriers against obtaining syringes from pharmacies. Prior
research has also found that hostile service environments
may increase the odds of improper syringe disposal [46].
Free printed materials about HIV, Hepatitis C, and STI
risk reduction and free blood pressure checks that are
commonly used to promote business ranked the first
and second most frequently used PDHRS. The other six
PDHRS targeting high risk populations were provided by
less than 3 % of pharmacies. Future pharmacy based
harm reduction interventions could begin with services
that are mutually beneficial to pharmacies and PWID.
Naloxone [47] would be an example of such service.
There were eight categories of services not currently
offered in pharmacies in Xichang. Lack of “free con-
doms”, “free syringes”, and “exchanging used syringes for
new ones” is probably linked with business concerns of
reduced revenue for these services [18, 29–31, 35–37].
Legal considerations [23] may contribute to the lack of
HIV testing [48–50], vaccinations for Hepatitis A and B
[51], syringe disposal [45], and directly dispensing
methadone [47, 52]. The dearth of “a written drug treat-
ment referral” may be due to lack of “time” and profes-
sional training for pharmacists [18, 29–31, 35, 37].
Financial concerns could be resolved by reimbursements,
similar to pharmacy vouchers, for syringes [19]. At the
time of investigation, HIV testing was only available in
medical facilities [48–50] not pharmacies. After approval
from China FDA, HIV test kits may become available in
pharmacies [48]. Currently, methadone clinics are only
government administered [7]. As an alternative, pharma-
cies in areas with high numbers of PWID could dispense
methadone [7, 52, 53], which may make MMT more
Table 5 Availability and feasibility for PDHRS among PWID in the last 12 months from Xichang, China 2012 (n = 403)
Service category Services currently available (No. (%)) Potential services (No. (%))
Offered/availabe Accepted/used€ Good idea to offer Personally use if offered
Printed materials about HIV/Hepatitis C/STIs risk reduction 68(16.9) 65(95.6) 384(95.3) 381(94.5)
Blood pressure check 45(11.2) 41(91.1) 369(91.6) 367(91.1)
Training/information about preventing overdoses 10(2.5) 10(100.0) 350(86.8) 347(86.1)
Training/information about how to inject safely 5(1.2) 5(100.0) 337(83.6) 334(82.9)
Training/information about how to prevent abscesses 3(0.7) 3(100.0) 353(87.6) 353(87.6)
Overdose medication (naloxone/narcan) 2(0.5) 2(100.0) 278(69.0) 277(68.7)
Sharps container to dispose of syringes 1(0.2) 1(100.0) 281(69.7) 276(68.5)
A written medical or social service referral 1(0.2) 1(100.0) 301(74.7) 302(74.9)
Free condoms 0 0 346(85.9) 340(84.4)
Vaccinations for hepatitis A/B 0 0 335(83.1) 326(80.9)
HIV testing 0 0 317(78.7) 308(76.4)
Free syringes 0 0 325(80.6) 322(79.9)
To dispose of used syringes 0 0 290(72.0) 285(70.7)
To exchange used syringes for new ones 0 0 287(71.2) 285(70.7)
A written drug treatment referral 0 0 280(69.5) 280(69.5)
Directly dispensing methadone 0 0 274(68.0) 270(67.0)
Abbreviations: PDHRS Pharmacy-Delivered Services, HIV human immunodeficiency virus, STIs, sexually transmitted infections
€: n = offered or available in the last 12 months
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available and cost-effective than only dispensing at national
clinics [7] where discrimination and stigma have been doc-
umented [19, 20, 22, 23, 54]. Similarly, used syringes could
be disposed at pharmacies [46]. In order to offer greater
harm reduction services, pharmacy staff need training to
improve their knowledge and skills (including drug treat-
ment referrals) and enhanced sensitivity toward PWID.
Due to easy access at community health centers [49–51], it
is not necessary to provide vaccinations in pharmacies.
The limitations of the current study should be noted.
All data was based on self-reports. Snowball sampling was
used, and the participants were recruited primarily from
harm reduction sites limiting the generalizability of the
findings. Future studies should recruit PWID from the
general communities. Respondent driven sampling could
be applied [55]. Further studies should also examine bar-
riers for pharmacies to provide harm reduction services.
Conclusions
Although community pharmacies have been providing
services to PWID in many countries and in parts of
China, comprehensive PDHRS had not been reported in
Liangshan where HIV is prevalent and the major route of
HIV infection is injection drug use. The findings indicated
that NPSS from pharmacies provided most PWID with
new syringes, but disposal of used syringes was problem-
atic. At the time of investigation, 8 of 16 services were
already available. PWID were interested in using all the
potential PDHRS, if available. Of the 16 PDHRS, 14 were
feasible to be provided if pharmacies benefited financially
from providing such services. Future harm risk reduction
programs should provide the reimbursements for pharma-
cies and training for pharmacists.
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